Skip to content
VuFind
English
Deutsch
Español
Français
Italiano
日本語
Nederlands
Português
Português (Brasil)
中文(简体)
中文(繁體)
Türkçe
עברית
Gaeilge
Cymraeg
Ελληνικά
Català
Euskara
Русский
Čeština
Suomi
Svenska
polski
Dansk
slovenščina
اللغة العربية
বাংলা
Galego
Tiếng Việt
Hrvatski
हिंदी
Հայերէն
Українська
Sámegiella
Монгол
Language
All Fields
Title
Author
Subject
Call Number
ISBN/ISSN
Tag
Find
Advanced
10 YEARS EXPERIENCE OF TYROSIN...
Cite this
Text this
Email this
Print
Export Record
Export to RefWorks
Export to EndNoteWeb
Export to EndNote
Permanent link
10 YEARS EXPERIENCE OF TYROSINE KINASE INHIBITOR THERAPY FOR CML IN A SINGLE UK CENTRE: COMPARISON WITH PRE-TKI ERA AND EVALUATION OF 2013 ELN GUIDELINES
Bibliographic Details
Main Authors:
Khan, D
,
Roy, N
,
Bari, V
,
Vallance, G
,
Dreau, H
,
Littlewood, T
,
Peniket, A
,
Vyas, P
,
Foroni, L
,
Schuh, A
,
Mead, A
Format:
Conference item
Published:
2014
Holdings
Description
Similar Items
Staff View
Similar Items
Real‐world tyrosine kinase inhibitor treatment pathways, monitoring patterns and responses in patients with chronic myeloid leukaemia in the United Kingdom: the UK TARGET CML study
by: Milojkovic, D, et al.
Published: (2020)
Can EGFR-Tyrosine Kinase Inhibitors (TKI) Alone Without Talc Pleurodesis Prevent Recurrence of Malignant Pleural Effusion (MPE) in Lung Adenocarcinoma
by: Verma, Akash, et al.
Published: (2017)
Telomere length shortening in CML is associated with reduced time to accelerated phase but does not influence overall survival.
by: Boultwood, J, et al.
Published: (1999)
USING ELNES WITH PARALLEL EELS FOR DIFFERENTIATING BETWEEN A-SI-X THIN-FILMS
by: Auchterlonie, G, et al.
Published: (1989)
Progress with interferon in CML--results of the MRC UK CML III study.
by: Shepherd, P, et al.
Published: (1996)